Scancell Share Discussion Threads

[inanaco] 07/10/2024 08:27

so I agree with EE here .........

emptyend

Posts: 847

Price: 13.25

No Opinion

RE: ImmunotherapyToday 08:40
As I said below, chelsea:

…..if they are investigating (with PR hoo-hah and some expense) how to turn 50% success rates into something higher for melanoma and a few other cancers……;and then along comes some “surprise̶1; news just after their assessment project has started that (say) 85% of patients respond to another melanoma vaccine…..then that is something which simply cannot be ignored!

[inanaco] 07/10/2024 08:25

Jul 2029
Transition data to open source, for access by academic institutions.

a lot of money in analyses spent



but will you see any benefit before 2035 ? assuming you can translate the data

into pre clinical candidates

and only in 4 cancer types ....

of which Scancell could be miles ahead in those 4 by then


and

NPM
In bladder carcinoma, the progression of the disease to an advanced stage correlates with the expression of nucleophosmin (NPM). NPM is citrullinated by PAD4, which may result in its transport to the cytoplasm for degradation



Results In contrast to NPM regulation, which is mediated by peptidylarginine deiminase (PAD4) citrullination of arginine at position 197, only citrullinated NPM266-285 peptide induced a citrulline-specific CD4 T cell response in transgenic mice models expressing human HLA-DP4 or HLA-DR4. Vaccinations with the NPM266-285cit peptide stimulated antitumor responses that resulted in dramatic tumor therapy, greatly improved survival, and protected against rechallenge without further vaccination.

[inanaco] 07/10/2024 07:40

13.41 £1000 inc fee

[inanaco] 07/10/2024 07:38

one other point

Scancell already know the data ............

they can calculate ORR on any two patient number


ATB

[inanaco] 07/10/2024 07:35

your not reading the thread ruck read back only one day

[ruckrover] 07/10/2024 07:32

"ref valuation Bermuda"What valuation are we talking about?

[ruckrover] 07/10/2024 07:30

Inan, That's great, I hope you are profit tomorrow - it is after all a Tuesday in October. Let's hope my statistical analysis is correct in this instance!

[inanaco] 07/10/2024 07:18

ref valuation Bermuda

The end of the scope and Modify trials are not after the interim analysis in This Qtr and H1 2025

OS and PFS data still to come

ATB

and that valuation included SCIB2

[inanaco] 07/10/2024 07:14

anyway cash flow is good so sent up another £1000

will buy soon

[inanaco] 07/10/2024 07:10

There are plenty of people who agree with it. It is a well known and documented statistical technique. If I were presented with the data set under discussion in my job I would for sure exclude the -68. It would actually be disastrous if I included it. So statistically I am correct.


that is because your maths model was dreadful



"""Just be a little more open minded, tolerant and humble and this will be a much better board."""

you mean accept Poor quality posts ? without challenge

like the migrants are eating the Pets ....

[sci102] 07/10/2024 06:59

You should give it a rest Ruck. Trimming may be valid if the purpose is to forecast sales or stock (merchandise) but it does not apply to clinical trials like this one. The only reason they would exclude patients is if they broke protocol or an error in prescreening and even then sponsors must report on full dataset regardless and then do a secondary analysis that includes exact justification about the exclusions. There is no such thing as trimming outliers in trials like this one.

[ruckrover] 07/10/2024 06:53

Inan,"find somebody that does agree with it ..."There are plenty of people who agree with it. It is a well known and documented statistical technique. If I were presented with the data set under discussion in my job I would for sure exclude the -68. It would actually be disastrous if I included it. So statistically I am correct.Whether it is appropriate to use this technique when analysing tumour shrinkage in this particular data set is a different matter. I think it is but my bias is statistics. Bermuda thinks it isn't but his bias is perhaps not statistics but Biotech. What is important is we can have a civilised debate about and disagree. I don't feel a need to fabricate evidence and twist posts in an attempt to make him look stupid - he clearly isn't. You are evidently among the most researched and knowledgeable on the science of immunology as applied by Scancell. However, you narrow vision and claims of expertise in areas you know nothing about severely damages your credibility. Just be a little more open minded, tolerant and humble and this will be a much better board.

[inanaco] 07/10/2024 06:44

so there we have it ....

Ruck is convinced removing patients from a data set on a trial is Good practice so that you get the data set you want

and bermuda believes he is correct and we did not have a vaccine platform


my my what ever next

Lozan and the terrace

[inanaco] 07/10/2024 06:37

""""Also worth noting that Scancell simply don't have a vaccine platform that can be quickly developed and manufactured yet and at the moment speed is of the essence, hence the focus on mRNA vaccines.""""


"""The covid post was indeed without the benefit of hindsight, it was my opinion at the time and turned out to be absolutely correct,"""

but we did !!!!!!!!!!!!!!!!!!!#

indeed Immbio used it against FLU called Immunobody a vaccine platform

ATB

[inanaco] 07/10/2024 06:33

you have to live with it .......... they are your posts !!!

""" For example my exclusion of “outliers̶1; in the analysis of a data set. Currently we disagree on this."""
😂

find somebody that does agree with it ...

I suggest you are the “outlier”;

[ruckrover] 07/10/2024 06:23

Bermuda,It is fairly obvious he spends his life filing, cataloging and indexing posts. Your question is valid - why? Any opinion, views, predictions could change in light of new evidence, data and even sentiment. Most of us are able to revise our thinking based on new light. I often refine or even reverse my view within hours let alone 3 years! Other times I stick to my guns. For example my exclusion of "outliers" in the analysis of a data set. Currently we disagree on this. We both can live with that. Our experience and understanding differs as of now but that doesn't mean either of us could change our view.

[inanaco] 06/10/2024 18:30

your post on the vaccine was Before Scancell developed Covidity Bermuda

you can't use hindsight as a defence

after all Scancell may not have developed it, if they had a crystal ball

however it gave us a chance to test avidmab


the point about is not about the valuation or scancell may not be the next BioNtech

it endless negativity and as you have said non committal

you place Risk far higher than it should be .... but without really studying it

which is why you could never answer

which one has failed Post Keytruda or SCIB1

because if you had, you would have come out with the same Opinion AS ME and with all the info that's come out over the last 12 months, you have not announced a change

RISK

[ruckrover] 06/10/2024 18:20

Inan, "meanwhile i will keep buying which gives you great displeasure"Not at all, why would it. Buy as many as you like it's your money.Without buyers, no one would be able to sell. Hopefully you will be hoovering up of mine at a £1 in a year or two.

[bermudashorts] 06/10/2024 17:56

inanaco,

Your 12947 and 12948 both with paragraphs taken out of context from posts made probably at least 3 years ago - do you save all these posts to a file or do you wade back over thousands of posts to find them? Regardless of your answer, with reference to your 12947 this is the part of my post from 2020? that you have chosen to quote:-

'"Also worth noting that Scancell simply don't have a vaccine platform that can be quickly developed and manufactured yet and at the moment speed is of the essence, hence the focus on mRNA vaccines.'

Below is a direct quote from Lindy Durrant when she's asked about Scancell's covid vaccine in an interview broadcast last month:-

' I think the lesson we learned is you cannot compete with big pharma. They moved very fast with covid vaccines, they did a great number of patients, they had everything in place and resources to do it. We just couldn't compete. Although the vaccines (Covidity) looked promising I'm not sure there was any benefit over the RNA vaccines that went much faster and got approval much quicker. So at this point we're not pursuing the covid vaccine'

Regarding your 12948, why don't you keep that one and post it in H1 next year when the iSCIB1 and Modi1 results are in. If Scancell's market cap at that stage is indeed £3.75 billion you will have the pleasure of saying I told you so but it's a bit premature at the moment.

[inanaco] 06/10/2024 12:05

anyway loz

we have established the hardcore used over 7 years toil ... Glass

what holds the glass in ? as you need steps hence the description of a terrace rather than a Patio

whats the surface finish now ?

so many questions

[inanaco] 06/10/2024 11:59

meanwhile i will keep buying which gives you great displeasure

[inanaco] 06/10/2024 11:58

RuckRover - 06 Oct 2024 - 10:03:56 - 12930 of 12951 Scancell - Pot of Gold or POS? - SCLP
Inan,
That was my initial thought as well.


LOL

but carry on .... 😏

you and Bermuda can get back to "group Risk and hugs "

[inanaco] 06/10/2024 11:56

the reason why i questioned the 60% because i thought you meant this current trial

not the 2012 trial

[inanaco] 06/10/2024 11:55

but i would remind you Ruck ,.......

a rare event i know

ref the Right T cells


RuckRover - 06 Oct 2024 - 10:03:56 - 12930 of 12951 Scancell - Pot of Gold or POS? - SCLP
Inan,
That was my initial thought as well.
Response with current standard of care 50%
Response with SCIB1 mono therapy 60%
Response on SCOPE trial 70-85% (awaiting data to confirm)